Sol-Gel Technologies Other Current Assets 2016-2024 | SLGL
Sol-Gel Technologies other current assets from 2016 to 2024. Other current assets can be defined as field containing the sum of all current assets that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
Sol-Gel Technologies Annual Other Current Assets
(Millions of US $) |
| 2023 |
$10 |
| 2022 |
$13 |
| 2021 |
$21 |
| 2020 |
$21 |
| 2019 |
$ |
| 2018 |
$1 |
| 2017 |
$4 |
| 2016 |
$ |
| 2015 |
$ |
Sol-Gel Technologies Quarterly Other Current Assets
(Millions of US $) |
| 2024-06-30 |
$4 |
| 2024-03-31 |
$5 |
| 2023-12-31 |
$10 |
| 2023-09-30 |
$12 |
| 2023-06-30 |
$14 |
| 2023-03-31 |
$9 |
| 2022-12-31 |
$13 |
| 2022-09-30 |
$17 |
| 2022-06-30 |
$21 |
| 2022-03-31 |
$9 |
| 2021-12-31 |
$21 |
| 2021-09-30 |
|
| 2021-06-30 |
$21 |
| 2021-03-31 |
$22 |
| 2020-12-31 |
$21 |
| 2020-09-30 |
$21 |
| 2020-06-30 |
$20 |
| 2020-03-31 |
$18 |
| 2019-12-31 |
|
| 2019-09-30 |
|
| 2019-06-30 |
|
| 2019-03-31 |
$1 |
| 2018-06-30 |
$1 |
| 2018-03-31 |
$5 |
| 2017-12-31 |
|
| 2017-09-30 |
$5 |
| 2017-06-30 |
|
| 2016-12-31 |
$1 |
| 2015-12-31 |
$0 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.012B |
$0.002B |
|
Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for the treatment of acne vulgaris, which are in its clinical stage. Sol-Gel Technologies Ltd.is based in Israel.
|
